

MUTANT INTERLEUKIN-2 POLYPEPTIDES

Abstract

The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the α -subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2
5 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.

10 (No suitable figure)